Trial Profile
A Randomized Study of the Safety and Efficacy of BIO-11006 in Treatment of Advanced Non-Small Cell Lung Cancer in Patients Who Are Not Candidates for Curative Surgery and/or Radiation and Who Are Receiving Pemetrexed and Carboplatin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2023
Price :
$35
*
At a glance
- Drugs BIO-11006 (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors BioMarck Pharmaceuticals
- 01 Jun 2020 Results published in the BioMarck Pharmaceuticals Media Release.
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
- 15 May 2020 Status changed from active, no longer recruiting to completed.